Reply to: Axel Heidenreich. Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer. Eur Urol 2021;79:605-6

Affiliations

¹ Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil. Electronic address: jeanlestingi@gmail.com.
² Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
³ Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Editorial

Jean F P Lestingi et al. Eur Urol. 2021 May.

. 2021 May;79(5):607-608.

doi: 10.1016/j.eururo.2021.01.041. Epub 2021 Feb 16.

¹ Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil. Electronic address: jeanlestingi@gmail.com.
² Instituto do Cancer do Estado de Sao Paulo, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
³ Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

No abstract available

Comment on

Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial.
Lestingi JFP, Guglielmetti GB, Trinh QD, Coelho RF, Pontes J Jr, Bastos DA, Cordeiro MD, Sarkis AS, Faraj SF, Mitre AI, Srougi M, Nahas WC. Lestingi JFP, et al. Eur Urol. 2021 May;79(5):595-604. doi: 10.1016/j.eururo.2020.11.040. Epub 2020 Dec 5. Eur Urol. 2021. PMID: 33293077 Clinical Trial.
Still Unanswered: The Role of Extended Pelvic Lymphadenectomy in Improving Oncological Outcomes in Prostate Cancer.
Heidenreich A. Heidenreich A. Eur Urol. 2021 May;79(5):605-606. doi: 10.1016/j.eururo.2021.01.033. Epub 2021 Feb 13. Eur Urol. 2021. PMID: 33593651 No abstract available.